

Deep Eutectic Solvents- a New Additive in the Encapsulation of Lipase B from *Candida antarctica*: Biocatalytic Applications

Adrian Dudu^[a], Csaba Bencze^[a], Csaba Paizs^[a] and Monica Toşa^[a]

[a] Eng. A. Dudu, Lect. C. Bencze, Prof. C. Paizs, Prof. M. Toşa

Department of Enzymology and Advanced Biocatalysis Research Center

Institution Babeş-Bolyai University, Faculty of Chemistry and Chemical Engineering

Address Arany Janos street no. 11, 400028, Cluj Napoca, Romania

E-mail: monica.tosa@ubbcluj.ro

Supporting Information

Detailed experimental results

Here we report the detailed results obtained in our study.

Table S1. Solvent screening results.

Sol-gel code	Solvent	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i> -value*
SG-1	<i>n</i> -hexane	23.2 ± 2.4	18.3 ± 2.1	>200
	MTBE	11.0 ± 1.1	9.9 ± 0.8	>200
	DIPE	17.4 ± 1.5	14.8 ± 1.1	>200
	2-Methyl-THF	4 ± 1.5	3.8 ± 1.4	>200
SG-2	<i>n</i> -hexane	95.8 ± 0.0	49.0 ± 0.0	»200
	MTBE	56.6 ± 1.6	36.1 ± 0.7	>200
	DIPE	80.8 ± 6.9	44.6 ± 2.1	»200
	2-Methyl-THF	4.1 ± 1.5	3.9 ± 1.4	>200
SG-3	<i>n</i> -hexane	90.6 ± 0.2	47.5 ± 0.1	»200
	MTBE	18.5 ± 2.8	15.6 ± 2.0	>200
	DIPE	85.3 ± 5.3	46.0 ± 1.6	»200
	2-Methyl-THF	5.7 ± 1.5	5.4 ± 1.3	>200
SG-4	<i>n</i> -hexane	33.6 ± 1.1	25.1 ± 1.7	>200
	MTBE	70.3 ± 1.0	41.3 ± 0.3	>200
	DIPE	17.5 ± 0.1	14.9 ± 0.1	>200
	2-Methyl-THF	2.7 ± 1.4	2.2 ± 0.8	199
SG-5	<i>n</i> -hexane	94.3 ± 0.8	48.5 ± 0.3	»200
	MTBE	76.4 ± 3.3	43.3 ± 1.1	>200
	DIPE	85.7 ± 1.1	46.2 ± 0.3	»200
	2-Methyl-THF	15.5 ± 1.1	13.4 ± 0.8	>200
SG-6	<i>n</i> -hexane	93.4 ± 0.3	48.3 ± 0.1	»200
	MTBE	21.3 ± 3.6	17.5 ± 2.5	>200
	DIPE	45.9 ± 3.2	31.4 ± 1.6	>200
	2-Methyl-THF	4.2 ± 0.7	4.1 ± 0.6	>200
SG-7	<i>n</i> -hexane	73.6 ± 2.7	42.4 ± 0.9	>200
	MTBE	56.7 ± 2.2	36.2 ± 0.9	>200
	DIPE	83.1 ± 7.5	45.3 ± 2.4	»200
	2-Methyl-THF	8.6 ± 0.5	7.9 ± 0.4	>200

*99.9% product enantiomeric excess

Table S2. Substrate: enzyme weight *ratio* screening results.

Sol-gel code	Substrate: enzyme <i>ratio</i> [w/w %]	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i>- value*
SG-2	20:1	85.9 ± 0.2	46.2 ± 0.1	»200
	40:1	81.0 ± 4.9	44.7 ± 1.5	»200
	60:1	79.3 ± 3.9	44.2 ± 1.2	>200
	80:1	64.8 ± 0.8	39.3 ± 0.3	>200
	100:1	46.1 ± 2.3	31.6 ± 1.1	>200
SG-3	20:1	94.5 ± 0.7	48.6 ± 0.4	»200
	40:1	88.0 ± 1.3	46.8 ± 0.4	»200
	60:1	85.5 ± 0.8	46.1 ± 0.2	»200
	80:1	81.7 ± 0.2	45.0 ± 0.0	»200
	100:1	76.0 ± 2.7	43.2 ± 0.9	>200
SG-5	20:1	95.1 ± 4.8	48.7 ± 1.3	»200
	40:1	93.5 ± 4.8	48.3 ± 1.1	»200
	60:1	91.1 ± 6.1	47.6 ± 1.7	»200
	80:1	86.0 ± 4.6	46.2 ± 1.4	»200
	100:1	75.4 ± 6.1	42.9 ± 2.0	>200
SG-6	20:1	86.5 ± 0.9	46.4 ± 0.3	»200
	40:1	81.8 ± 3.6	45.0 ± 1.1	»200
	60:1	78.8 ± 5.7	44.0 ± 1.8	>200
	80:1	71.8 ± 4.6	41.8 ± 1.5	>200
	100:1	62.0 ± 0.1	38.3 ± 0.0	>200
SG-7	20:1	92.4 ± 1.6	48 ± 0.5	»200
	40:1	87.5 ± 0.8	46.7 ± 0.2	»200
	60:1	86.9 ± 0.8	46.5 ± 0.2	»200
	80:1	84.1 ± 3.1	45.7 ± 0.9	»200
	100:1	76.1 ± 2.1	43.2 ± 0.7	>200

*99.9% product enantiomeric excess

Table S3. Substrate: acyl donor molar *ratio* screening results.

Sol-gel code	Substrate: acyl donor <i>ratio</i> [mol/mol %]	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i> -value*
SG-2	1:1	69.7 ± 1.0	41.1 ± 0.3	>200
	1:2	77.8 ± 6.3	43.7 ± 2.0	>200
	1:3	80.4 ± 4.9	44.5 ± 1.6	»200
	1:4	83.0 ± 5.1	45.3 ± 1.6	»200
SG-3	1:1	73.6 ± 6.3	42.3 ± 2.1	>200
	1:2	80.1 ± 2.1	44.4 ± 0.7	»200
	1:3	82.0 ± 0.4	45.1 ± 0.1	»200
	1:4	85.0 ± 2.4	46.0 ± 0.7	»200
SG-5	1:1	53.4 ± 0.9	34.8 ± 0.4	>200
	1:2	57.2 ± 1.2	36.4 ± 0.5	>200
	1:3	59.1 ± 2.8	37.1 ± 1.2	>200
	1:4	81.2 ± 6.7	44.8 ± 2.0	»200
SG-6	1:1	79.3 ± 1.0	44.2 ± 0.4	>200
	1:2	79.6 ± 1.2	44.3 ± 0.4	>200
	1:3	82.0 ± 2.5	45.0 ± 0.8	»200
	1:4	85.0 ± 0.2	45.9 ± 0.1	»200
SG-7	1:1	53.4 ± 0.2	34.8 ± 0.1	>200
	1:2	66.4 ± 0.6	39.9 ± 0.2	>200
	1:3	67.9 ± 1.1	40.5 ± 0.4	>200
	1:4	75.9 ± 4.0	43.1 ± 1.3	>200

*99.9% product enantiomeric excess

Table S4. Temperature screening results.

Sol-gel code	Temperature [°C]	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i> -value*
SG-3	30	89.1 ± 3.4	47.1 ± 1.0	»200
	40	58.3 ± 5.1	36.7 ± 2.1	>200
	50	94.1 ± 4.0	48.4 ± 1.1	»200
	60	88.8 ± 8.1	46.9 ± 2.3	»200
SG-6	30	64.8 ± 24.4	38 ± 9.2	>200
	40	93.8 ± 0.1	48.4 ± 0.1	»200
	50	94.3 ± 1.1	47.3 ± 0.8	»200
	60	94.8 ± 1.6	48.7 ± 0.4	»200

*99.9% product enantiomeric excess

Table S5. Acyl donor screening results.

Sol-gel code	Time [h]	Acyl donor	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i> -value*
SG-3	1	Vinyl acetate	62.4 ± 3.9	38.4 ± 1.5	>200
	2		76.3 ± 2.8	43.3 ± 0.9	>200
	3		86.0 ± 3.8	46.2 ± 1.1	»200
	4		97.4 ± 2.5	49.3 ± 0.7	»200
	1	Vinyl propionate	51.1 ± 3.2	33.8 ± 1.4	>200
	2		59.6 ± 0.7	37.3 ± 0.3	>200
	3		74.7 ± 3.3	42.7 ± 1.1	>200
	4		91.5 ± 1.0	47.8 ± 0.3	»200
	1	Vinyl decanoate	43.1 ± 0.3	30.1 ± 0.2	>200
	2		56.4 ± 1.9	36.1 ± 0.8	>200
	3		84.6 ± 1.7	45.8 ± 0.5	»200
	4		91.3 ± 0.7	47.7 ± 0.2	»200

*99.9% product enantiomeric excess

Table S6. Reusability study results.

Sol-gel code	Reaction cycle	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i> -value*
SG-3	1	99.9 ± 0.0	50.0 ± 0.0	»200
	2	99.9 ± 0.0	50.0 ± 0.0	»200
	3	94.3 ± 0.3	48.5 ± 0.1	»200
	4	90.5 ± 3.0	47.5 ± 0.8	»200
	5	85.2 ± 1.6	46.0 ± 0.5	»200
	6	79.8 ± 0.2	44.4 ± 0.1	>200
	7	75.6 ± 3.0	43.0 ± 1.0	>200
	8	71.1 ± 2.8	41.5 ± 1.0	>200
	9	54.8 ± 0.4	35.4 ± 0.2	>200
	10	29.1 ± 0.3	22.5 ± 0.2	>200

*99.9% product enantiomeric excess

Table S7. Substrate concentration screening results.

Sol-gel code	Substrate concentration [mM]	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i> -value*
SG-3	25	79.0 ± 6.6	44.0 ± 2.1	>200
	50	86.4 ± 3.7	46.3 ± 1.1	»200
	75	83.8 ± 2.2	45.6 ± 0.7	»200
	100	80.0 ± 4.5	44.4 ± 1.4	»200
	250	65.4 ± 6.1	39.5 ± 2.2	>200
	500	53.0 ± 6.7	34.5 ± 2.9	>200
	750	36.1 ± 2.5	26.5 ± 1.4	>200

*99.9% product enantiomeric excess

Table S8. Synergetic effect study results.

Sol-gel code	Substrate enantiomeric excess [%]	Conversion [%]	<i>E</i>-value*
SG-31	63.3 ± 6.8	38.7 ± 2.5	>200
SG-32	79.5 ± 0.8	44.3 ± 0.3	>200
SG-33	52.4 ± 6.6	34.3 ± 2.8	>200
SG-3	90.2 ± 5.3	47.4 ± 1.5	»200

*99.9% product enantiomeric excess

Chromatographic conditions for compounds C-I

Oven temperatures and analysis time for compounds **C-I** (Figure 9) are presented in Table S9.

Table S9. Chromatographic conditions for the analysis of compounds **C-I**.

Compound	Oven temperature [°C]	Analysis time [min]
C	160	9.5
D	160	8.5
E	160	4.5
F	110	4.5
G	120	4.8
H	120	8.8
I	160	12.5

Examples of chromatograms

In this section we present some examples of chromatograms obtained when analyzing the experiments performed during the present study.




Figure S1. Solvent screening for biocatalyst SG-6; **a-** *n*-hexane, **b-** MTBE, **c-** DIPE, **d-** 2-Methyl-THF.




Figure S2. Substrate: enzyme ratio (w/w %) screening for biocatalyst SG-3; **a-** 20:1 weight ratio, **b-** 40:1 weight ratio, **c-** 60:1 weight ratio.




Figure S4. Substrate: acyl donor *ratio* (mol/mol %) screening for biocatalysts SG-3 and SG-6; **a-** 1:1 molar *ratio* for SG-3, **b-** 1:3 molar *ratio* for SG-3, **c-** 1:2 molar *ratio* for SG-6, **d-** 1:4 molar *ratio* for SG-6.






Figure S5. Time profile for the reaction mediated by SG-3, part of the acyl donor screening experiments; **a-** after 1 h, **b-** after 2 h, **c-** after 3 h, **d-** after 4 h.




a




b


Figure S6. Temperature screening for biocatalyst SG-3; **a**- 40 °C, **b**- 30 °C.




a



b



c



d

Figure S7. Transesterification of compounds **B** (a), **A** (b), **D** (c) and **I** (d) mediated by SG-3 using the optimal reaction conditions.